Actavis Inc (ACT) 213.66 $ACT
Mylan (MYL) Joins the Tax-Inversion Wave - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Jul 16, 12:03PM CDT
More M&A activity involving tax-inversion can be expected in the days ahead.
Facebook, Apple Suppliers Lead 5 Big-Cap All-Stars
at Investor's Business Daily - Wed Jul 16, 8:16AM CDT
Looking for Wall Street's stock all-stars? IBD's Screen of the Day is Big Cap Leaders, which includes the top-performing large-cap stocks with strong fundamentals and technicals. This article focuses on the screen's five companies including social...
Mylan to Buy Abbott Generic Drug Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:10PM CDT
Mylan (MYL) will buy Abbott's (ABT) non-U.S. developed markets specialty and branded generics business.
Actavis Fuels Growth With Acquisitions, New Generics
at Investor's Business Daily - Mon Jul 14, 4:30PM CDT
Actavis (ACT) has kept busy on the merger and acquisition trail the past couple of years. Since closing its acquisition of Forest Laboratories on July 2, when new CEO (and former Forest chief) Brenton Saunders took the helm, Actavis has completed a...
Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Mylan Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS) and Hospira, Inc. (NYSE: HSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4724-100free.
Actavis Confirms Generic Diclegis® Patent Challenge
PR Newswire - Fri Jul 11, 3:25PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis®, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 4:10PM CDT
Synergy Pharmaceuticals (SGYP) intends to start a pivotal phase III study on its lead pipeline candidate, plecanatide.
ACTAVIS
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
ACTAVIS (ACT), a drugmaker, filed for FDA to OK marketing dalfampridine extended release tabs, a generic of multiple sclerosis drug Ampyra.
Actavis Confirms Generic Ampyra® Patent Challenge
PR Newswire - Tue Jul 08, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra®, which is indicated as a treatment to improve walking in patients with multiple sclerosis.
Stocks Ease Off Lows; King Digital Turns Tail
at Investor's Business Daily - Tue Jul 08, 12:28PM CDT
Stocks were still firmly lower Tuesday afternoon, but they have come slightly off their worst levels. The Nasdaq trimmed a 1.8% loss to 1.4%. Energy, Internet and solar stocks continued to be the worst-performing groups in the stock market today....
M&A Activity Hits 7-Year Peak: Next 3 Takeover Targets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:29AM CDT
Global mergers and acquisitions (M&A) activity has heated up considerably in 2014.
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
Impax Acquires Generic Products from Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 11:00AM CDT
Impax Laboratories, Inc. (IPXL) announced that it has acquired two generic products from Actavis plc (ACT) for a cash consideration.
Impax reports purchase of two products from Actavis for undisclosed fee
M2 - Thu Jul 03, 6:31AM CDT
Specialist pharmaceutical company Impax Laboratories (NasdaqGS:IPXL) announced on Wednesday the completion of the acquisition of two generic products for cash consideration from Actavis (NYSE:ACT) under a Purchase Agreement and a Supply Agreement.
Actavis buys Furiex Pharmaceuticals in all-cash transaction
M2 - Thu Jul 03, 6:31AM CDT
Pharmaceutical company Actavis (NYSE:ACT) stated on Wednesday that its Forest Laboratories subsidiary has closed the acquisition of Furiex Pharmaceuticals (NasdaqGS:FURX) in USD1.1bn in cash.
What Stocks Top Funds Are Buying Now
at Investor's Business Daily - Wed Jul 02, 6:09PM CDT
The country's leading funds the past three months continued to add medical and transportation stocks to their portfolios as the stock market continued to defy the economy's wall of worry. Purchases were made as the Nasdaq kicked off the summer with a...
Impax Acquires Two Products from Actavis
PR Newswire - Wed Jul 02, 3:05PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has acquired from Actavis plc (NYSE: ACT) two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed.
Destination Maternity: Mothercare nixes proposals
AP - Wed Jul 02, 8:03AM CDT
PHILADELPHIA (AP) — Destination Maternity says the U.K.'s Mothercare has rejected two proposals to combine the businesses.
Mylan (MYL) Joins the Tax-Inversion Wave - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Jul 16, 12:03PM CDT
More M&A activity involving tax-inversion can be expected in the days ahead.
Facebook, Apple Suppliers Lead 5 Big-Cap All-Stars
at Investor's Business Daily - Wed Jul 16, 8:16AM CDT
Looking for Wall Street's stock all-stars? IBD's Screen of the Day is Big Cap Leaders, which includes the top-performing large-cap stocks with strong fundamentals and technicals. This article focuses on the screen's five companies including social...
Mylan to Buy Abbott Generic Drug Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:10PM CDT
Mylan (MYL) will buy Abbott's (ABT) non-U.S. developed markets specialty and branded generics business.
Actavis Fuels Growth With Acquisitions, New Generics
at Investor's Business Daily - Mon Jul 14, 4:30PM CDT
Actavis (ACT) has kept busy on the merger and acquisition trail the past couple of years. Since closing its acquisition of Forest Laboratories on July 2, when new CEO (and former Forest chief) Brenton Saunders took the helm, Actavis has completed a...
Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Mylan Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS) and Hospira, Inc. (NYSE: HSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4724-100free.
Actavis Confirms Generic Diclegis® Patent Challenge
PR Newswire - Fri Jul 11, 3:25PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis®, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 4:10PM CDT
Synergy Pharmaceuticals (SGYP) intends to start a pivotal phase III study on its lead pipeline candidate, plecanatide.
ACTAVIS
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
ACTAVIS (ACT), a drugmaker, filed for FDA to OK marketing dalfampridine extended release tabs, a generic of multiple sclerosis drug Ampyra.
Actavis Confirms Generic Ampyra® Patent Challenge
PR Newswire - Tue Jul 08, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra®, which is indicated as a treatment to improve walking in patients with multiple sclerosis.
Stocks Ease Off Lows; King Digital Turns Tail
at Investor's Business Daily - Tue Jul 08, 12:28PM CDT
Stocks were still firmly lower Tuesday afternoon, but they have come slightly off their worst levels. The Nasdaq trimmed a 1.8% loss to 1.4%. Energy, Internet and solar stocks continued to be the worst-performing groups in the stock market today....
M&A Activity Hits 7-Year Peak: Next 3 Takeover Targets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:29AM CDT
Global mergers and acquisitions (M&A) activity has heated up considerably in 2014.
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
Impax Acquires Generic Products from Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 11:00AM CDT
Impax Laboratories, Inc. (IPXL) announced that it has acquired two generic products from Actavis plc (ACT) for a cash consideration.
Impax reports purchase of two products from Actavis for undisclosed fee
M2 - Thu Jul 03, 6:31AM CDT
Specialist pharmaceutical company Impax Laboratories (NasdaqGS:IPXL) announced on Wednesday the completion of the acquisition of two generic products for cash consideration from Actavis (NYSE:ACT) under a Purchase Agreement and a Supply Agreement.
Actavis buys Furiex Pharmaceuticals in all-cash transaction
M2 - Thu Jul 03, 6:31AM CDT
Pharmaceutical company Actavis (NYSE:ACT) stated on Wednesday that its Forest Laboratories subsidiary has closed the acquisition of Furiex Pharmaceuticals (NasdaqGS:FURX) in USD1.1bn in cash.
What Stocks Top Funds Are Buying Now
at Investor's Business Daily - Wed Jul 02, 6:09PM CDT
The country's leading funds the past three months continued to add medical and transportation stocks to their portfolios as the stock market continued to defy the economy's wall of worry. Purchases were made as the Nasdaq kicked off the summer with a...
Impax Acquires Two Products from Actavis
PR Newswire - Wed Jul 02, 3:05PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has acquired from Actavis plc (NYSE: ACT) two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed.
Destination Maternity: Mothercare nixes proposals
AP - Wed Jul 02, 8:03AM CDT
PHILADELPHIA (AP) — Destination Maternity says the U.K.'s Mothercare has rejected two proposals to combine the businesses.
